

IMPACT OF INTOLERANCE ON PATIENT GOALS

Quinn is a mother of 3 and is constantly in motion. While achieving a durable response from her CML treatment, she deals with ongoing AEs that disrupt her active lifestyle.

Sokal risk score	Low risk (0.7)
Time since diagnosis	36 months
Current treatment	2nd-line TKI
Length of time on current treatment	12 months
Molecular status	0.5% BCR-ABL1
Persistent AE	Grade 2 fatigue

- Quinn has noted that her persistent AE has become intolerable, and is experiencing a sense of tiredness that is slowing her down and not allowing her to keep up with her kids' extracurricular activities. How would that influence your clinical assessment?
- According to the National Comprehensive Cancer Network® (NCCN®), patients with >0.1% to 1% BCR-ABL1 at 12 months have TKI-sensitive disease and patient goals may influence clinical considerations¹
- According to European LeukemiaNet (ELN) recommendations, patients with >0.1% to 1% BCR-ABL1 at 12 months should be carefully considered for continuation or change of treatment, depending on patient characteristics, comorbidities, and tolerance²

LEARN ABOUT UNMET NEEDS IN CML. [VISIT OUR SITE](#)

TARGETCML

AE, adverse event; CML, chronic myeloid leukemia; TKI, tyrosine kinase inhibitor.

References: 1. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Chronic Myeloid Leukemia V3.2022. © National Comprehensive Cancer Network, Inc. 2022. All rights reserved. Accessed April 15, 2022. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

2. Hochhaus A, Baccarani M, Silver RT, et al. *Leukemia*. 2020;34:966-984.

 **NOVARTIS**

Novartis Pharma AG

CH-4002 Basel Switzerland

© 2022 Novartis

5/22

205169

Novartis Pharmaceuticals Corporation

East Hanover, New Jersey 07936-1080

Patient portrayal.

